T. Rowe Price Associates
OVID icon

T. Rowe Price Associates’s Ovid Therapeutics OVID Stock Holding History

T. Rowe Price Associates’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$339K Buy
+125,725
New +$324K ﹤0.01% 2803
2025
Q2 		– Sell
-17,396
Closed -$6K – 3126
2025
Q1 		$6K Hold
17,396
– – ﹤0.01% 3032
2024
Q4 		$17K Hold
17,396
– – ﹤0.01% 2997
2024
Q3 		$21K Hold
17,396
– – ﹤0.01% 2987
2024
Q2 		$14K Hold
17,396
– – ﹤0.01% 2910
2024
Q1 		$54K Buy
17,396
+3,145
+22% +$10.5K ﹤0.01% 2865
2023
Q4 		$46K Buy
14,251
+837
+6% +$2.86K ﹤0.01% 2818
2023
Q3 		$52K Buy
13,414
+1,301
+11% +$4.68K ﹤0.01% 2774
2023
Q2 		$40K Sell
12,113
-15,387
-56% -$52.2K ﹤0.01% 2825
2023
Q1 		$71K Hold
27,500
– – ﹤0.01% 2741
2022
Q4 		$51K Hold
27,500
– – ﹤0.01% 2811
2022
Q3 		$51K Sell
27,500
-3,633
-12% -$7.6K ﹤0.01% 2837
2022
Q2 		$67K Sell
31,133
-6,828
-18% -$16.5K ﹤0.01% 2825
2022
Q1 		$119K Hold
37,961
– – ﹤0.01% 2820
2021
Q4 		$122K Hold
37,961
– – ﹤0.01% 2847
2021
Q3 		$128K Hold
37,961
– – ﹤0.01% 2799
2021
Q2 		$148K Buy
37,961
+1,213
+3% +$4.79K ﹤0.01% 2786
2021
Q1 		$148K Buy
+36,748
New +$122K ﹤0.01% 2742
2018
Q3 		– Sell
-184,811
Closed -$1.44M – 2598
2018
Q2 		$1.44M Sell
184,811
-115,669
-38% -$993K ﹤0.01% 1690
2018
Q1 		$2.12M Buy
300,480
+910
+0.3% +$7.36K ﹤0.01% 1557
2017
Q4 		$2.96M Sell
299,570
-62,070
-17% -$570K ﹤0.01% 1502
2017
Q3 		$2.97M Hold
361,640
– – ﹤0.01% 1507
2017
Q2 		$3.64M Buy
+361,640
New +$4.72M ﹤0.01% 1457

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

T. Rowe Price Associates's OVID Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Ovid Therapeutics (OVID) in Q2 2026: 125,725 shares worth $339K. The stake represents ﹤0.01% of the portfolio and ranks #2803 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in OVID as recently as Q1 2025.

T. Rowe Price Associates first reported a position in OVID in Q2 2017 and has held it in 23 quarters since. The position peaked at $3.64M in Q2 2017. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • T. Rowe Price Associates held 125,725 shares of Ovid Therapeutics worth $339K as of Q2 2026.
  • Ovid Therapeutics was a new T. Rowe Price Associates position in Q2 2026.
  • Ovid Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2803 holding.
  • T. Rowe Price Associates first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 23 quarters since.
  • T. Rowe Price Associates's Ovid Therapeutics position peaked at $3.64M in Q2 2017.
  • 131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.